Comparative Pharmacology
Head-to-head clinical analysis: RASUVO versus THIOGUANINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RASUVO versus THIOGUANINE.
RASUVO vs THIOGUANINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RASUVO is a biosimilar of adalimumab, a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecule expression and cytokine release.
Thioguanine is a purine analog that incorporates into DNA and RNA, inhibiting purine nucleotide synthesis and cell replication. It acts as an antimetabolite, specifically targeting S-phase of the cell cycle.
Subcutaneous injection: 200 mg once weekly.
2 mg/kg orally once daily for 4 weeks, then 2 mg/kg orally every other day; or 2-3 mg/kg/day orally for 5 days per cycle.
None Documented
None Documented
Approximately 11-17 days (mean 13 days); supports every-4-week dosing interval for methotrexate-naive patients and every-4-week or every-2-week dosing in combination with methotrexate.
Terminal half-life approximately 11 hours (range 5-16 hours) in adults; extends to 20-30 hours in renal impairment.
Primarily cleared via proteolysis; renal and fecal excretion of active drug minimal. No specific biliary or renal excretion as a percentage.
Primarily renal; 40% excreted unchanged in urine within 24 hours; minor biliary/fecal elimination (<10%).
Category C
Category D/X
Antimetabolite
Antimetabolite